Sweden's Modus Therapeutics narrows Q2 net loss, extends financing

Modus Therapeutics Holding AB

26/08/2026 07:10

Overview
Sweden biotech firm's Q2 net loss and loss per share narrowed from prior year
Company raised about 9.5 mln SEK via warrant exercise, extending financing into Q1 2027
Phase IIa CKD with anemia trial progressed, top-line data expected around year-end 2026/2027

Outlook
Modus expects top-line proof-of-concept data from Phase IIa CKD study around year-end 2026/2027
Company says it is financed into Q1 2027 and through expected top-line data readout

Result Drivers
CLINICAL TRIAL PROGRESS - Co said patient recruitment in Phase IIa CKD with anemia study continued as planned, with top-line data expected around year-end 2026/2027
SCIENTIFIC VALIDATION - Co presented preclinical and clinical data on sevuparin at major European scientific conferences and submitted a manuscript for peer review
FINANCING STRENGTHENED - Co raised about 9.5 mln SEK from warrant exercise, extending financing into Q1 2027

Company press release: ID:nMFN9nsf5X

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
SEK 0.03
 
Q2 Net Loss
 
SEK 4.65 mln
 

Reuters Recommended Reads
Aug 25 - Molecular Partners H1 net loss narrows on lower R&D expenses
Aug 25 - Canada's LSL Pharma Q2 revenue surges on acquisition boost, eye-drop launches
Aug 25 - Biopharma firm Vyome Holdings posts Q2 net loss

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)